Baidu
map

INTENS CARE MED:流感疫苗可降低老年重症监护患者的早期死亡风险

2019-08-03 海北 MedSci原创

最近,研究人员检查了流感疫苗接种是否会影响年龄≥65岁的重症监护病房(ICU)幸存者患心肌梗塞,中风,心力衰竭,肺炎和死亡的1年风险。

最近,研究人员检查了流感疫苗接种是否会影响年龄≥65岁的重症监护病房(ICU)幸存者患心肌梗塞,中风,心力衰竭,肺炎和死亡的1年风险。

该研究囊括了2005年至2015年期间在丹麦ICU住院并随后出院的所有老年(≥65岁)患者的丹麦重症监护数据库数据与其他医疗登记处的相关数据,包括季节性流感疫苗摄取数据。

研究人员计算了这些患者1年的心肌梗死,中风,心力衰竭或肺炎住院风险及其1年全因死亡风险,并使用Cox比例风险回归计算具有95%置信区间(CI)的危险比(HR),其中调整和倾向得分匹配用于处理混杂。

该研究共包括了89,818ICU幸存者。流感疫苗接种的患者(n = 34,871,39%)年龄较大,患有更多的慢性疾病,并使用了比未接种疫苗的患者更多的处方药。

接种疫苗的患者与未接种疫苗的患者的1年死亡率均有所下降(19.3%对18.8%;调整后HR0.9295CI 0.89-0.95)。

流感疫苗接种也与卒中风险降低有关(调整后HR0.84; 95CI 0.78-0.92),但对心肌梗死风险仅有很小的,非显着降低(调整HR0.93; 95CI 0.83-1.03 )。

疫苗接种与随后因心力衰竭或肺炎住院治疗无关。

倾向得分匹配分析证实了这些发现。

因此,与未接种疫苗的ICU幸存者相比,接种流感疫苗的ICU幸存者1年内卒中风险较低,1年死亡风险较低,而心肌梗死,心力衰竭或肺炎的住院治疗风险没有显着关联。

该研究结果支持年龄≥65岁的人接种流感疫苗。


原始出处:

Christian Fynbo Christiansen. Influenza vaccination and 1-year risk of myocardial infarction, stroke, heart failure, pneumonia, and mortality among intensive care unit survivors aged 65 years or older: a nationwide population-based cohort study. Intensive Care Medicine, 2019; 45 (7): 957 DOI: 10.1007/s00134-019-05648-4


本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2039079, encodeId=874d20390e92b, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Oct 06 01:50:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973256, encodeId=257119e3256dc, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Fri Mar 20 23:50:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018152, encodeId=4cad2018152b1, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sat Feb 15 03:50:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255889, encodeId=d89412558891e, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551161, encodeId=2bca15511616f, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609903, encodeId=5519160990378, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370747, encodeId=b4d13e074707, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4e15154495, createdName=146a2b7bm80暂无昵称, createdTime=Sun Aug 04 10:47:21 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370746, encodeId=a4083e07467e, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/01/73f851fad9c1b1deb5be0b41debe011b.jpg, createdBy=f3985124004, createdName=小mon, createdTime=Sun Aug 04 10:08:01 CST 2019, time=2019-08-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2039079, encodeId=874d20390e92b, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Oct 06 01:50:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973256, encodeId=257119e3256dc, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Fri Mar 20 23:50:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018152, encodeId=4cad2018152b1, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sat Feb 15 03:50:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255889, encodeId=d89412558891e, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551161, encodeId=2bca15511616f, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609903, encodeId=5519160990378, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370747, encodeId=b4d13e074707, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4e15154495, createdName=146a2b7bm80暂无昵称, createdTime=Sun Aug 04 10:47:21 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370746, encodeId=a4083e07467e, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/01/73f851fad9c1b1deb5be0b41debe011b.jpg, createdBy=f3985124004, createdName=小mon, createdTime=Sun Aug 04 10:08:01 CST 2019, time=2019-08-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2039079, encodeId=874d20390e92b, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Oct 06 01:50:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973256, encodeId=257119e3256dc, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Fri Mar 20 23:50:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018152, encodeId=4cad2018152b1, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sat Feb 15 03:50:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255889, encodeId=d89412558891e, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551161, encodeId=2bca15511616f, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609903, encodeId=5519160990378, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370747, encodeId=b4d13e074707, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4e15154495, createdName=146a2b7bm80暂无昵称, createdTime=Sun Aug 04 10:47:21 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370746, encodeId=a4083e07467e, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/01/73f851fad9c1b1deb5be0b41debe011b.jpg, createdBy=f3985124004, createdName=小mon, createdTime=Sun Aug 04 10:08:01 CST 2019, time=2019-08-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2039079, encodeId=874d20390e92b, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Oct 06 01:50:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973256, encodeId=257119e3256dc, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Fri Mar 20 23:50:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018152, encodeId=4cad2018152b1, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sat Feb 15 03:50:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255889, encodeId=d89412558891e, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551161, encodeId=2bca15511616f, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609903, encodeId=5519160990378, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370747, encodeId=b4d13e074707, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4e15154495, createdName=146a2b7bm80暂无昵称, createdTime=Sun Aug 04 10:47:21 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370746, encodeId=a4083e07467e, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/01/73f851fad9c1b1deb5be0b41debe011b.jpg, createdBy=f3985124004, createdName=小mon, createdTime=Sun Aug 04 10:08:01 CST 2019, time=2019-08-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2039079, encodeId=874d20390e92b, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Oct 06 01:50:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973256, encodeId=257119e3256dc, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Fri Mar 20 23:50:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018152, encodeId=4cad2018152b1, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sat Feb 15 03:50:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255889, encodeId=d89412558891e, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551161, encodeId=2bca15511616f, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609903, encodeId=5519160990378, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370747, encodeId=b4d13e074707, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4e15154495, createdName=146a2b7bm80暂无昵称, createdTime=Sun Aug 04 10:47:21 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370746, encodeId=a4083e07467e, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/01/73f851fad9c1b1deb5be0b41debe011b.jpg, createdBy=f3985124004, createdName=小mon, createdTime=Sun Aug 04 10:08:01 CST 2019, time=2019-08-04, status=1, ipAttribution=)]
    2019-08-05 bioon6
  6. [GetPortalCommentsPageByObjectIdResponse(id=2039079, encodeId=874d20390e92b, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Oct 06 01:50:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973256, encodeId=257119e3256dc, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Fri Mar 20 23:50:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018152, encodeId=4cad2018152b1, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sat Feb 15 03:50:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255889, encodeId=d89412558891e, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551161, encodeId=2bca15511616f, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609903, encodeId=5519160990378, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370747, encodeId=b4d13e074707, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4e15154495, createdName=146a2b7bm80暂无昵称, createdTime=Sun Aug 04 10:47:21 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370746, encodeId=a4083e07467e, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/01/73f851fad9c1b1deb5be0b41debe011b.jpg, createdBy=f3985124004, createdName=小mon, createdTime=Sun Aug 04 10:08:01 CST 2019, time=2019-08-04, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2039079, encodeId=874d20390e92b, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Oct 06 01:50:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973256, encodeId=257119e3256dc, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Fri Mar 20 23:50:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018152, encodeId=4cad2018152b1, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sat Feb 15 03:50:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255889, encodeId=d89412558891e, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551161, encodeId=2bca15511616f, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609903, encodeId=5519160990378, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370747, encodeId=b4d13e074707, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4e15154495, createdName=146a2b7bm80暂无昵称, createdTime=Sun Aug 04 10:47:21 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370746, encodeId=a4083e07467e, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/01/73f851fad9c1b1deb5be0b41debe011b.jpg, createdBy=f3985124004, createdName=小mon, createdTime=Sun Aug 04 10:08:01 CST 2019, time=2019-08-04, status=1, ipAttribution=)]
    2019-08-04 146a2b7bm80暂无昵称

    很好

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2039079, encodeId=874d20390e92b, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Oct 06 01:50:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973256, encodeId=257119e3256dc, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Fri Mar 20 23:50:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018152, encodeId=4cad2018152b1, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sat Feb 15 03:50:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255889, encodeId=d89412558891e, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551161, encodeId=2bca15511616f, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609903, encodeId=5519160990378, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Aug 05 07:50:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370747, encodeId=b4d13e074707, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4e15154495, createdName=146a2b7bm80暂无昵称, createdTime=Sun Aug 04 10:47:21 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370746, encodeId=a4083e07467e, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/01/73f851fad9c1b1deb5be0b41debe011b.jpg, createdBy=f3985124004, createdName=小mon, createdTime=Sun Aug 04 10:08:01 CST 2019, time=2019-08-04, status=1, ipAttribution=)]
    2019-08-04 小mon

    挺好

    0

相关资讯

Intens Care Med:重症幸存者流感疫苗接种与1年心肌梗死、卒中、心衰、肺炎和死亡风险

由此可见,与未接种疫苗的ICU幸存者相比,接种流感疫苗的ICU幸存者1年内卒中风险较低,1年死亡风险较低,而与心肌梗死、心力衰竭或肺炎住院治疗的风险没有显著关联。该研究结果支持年龄≥65岁的人接种流感疫苗。

卫健委回应流感疫苗缺货:供应平稳 已接种1097万支

1月25日,国家卫生健康委员会召开新闻发布会,介绍冬春季传染病防控和节日常见病预防与应对有关情况。

为什么老年人打流感疫苗,效果可能会差?

先提出一个问题,为什么有些老年人群打了流感疫苗后,效果较差呢? 2月20日,《细胞—宿主与微生物》杂志发表一项新发现:流感疫苗在老年人群中效果可能较差的原因,主要与执行体液免疫的B淋巴细胞(人体的一种免疫细胞)有关,B细胞难以产生可充分适应并对抗新出现的流感病毒株的抗体。

世卫组织发布年度北半球季节性流感疫苗组份信息

世界卫生组织于21日在北京发布2019-2020年度北半球流感疫苗组份信息,将世界卫生组织的推荐建议与科学证据一起传达给监管机构和全球疫苗生产商。这是世卫组织20年来首次在其总部之外的地点举办北半球疫苗组份推荐会。世界卫生组织推荐的2019-2020年度北半球季节性流感疫苗组份信息如下:-A/Brisbane/02/2018 (H1N1)pdm09类似病毒;-A(H3N2)亚型:延迟公布-B/Co

国家卫健委:流感疫苗供需基本平衡,还有300多万支未使用

1月25日,记者从国家卫生健康委员会召开的新闻发布会上获悉,我国流感疫苗供需基本平衡,根据对流感疫苗使用情况统计,针对此次流感流行季我国疾控部门实际采购1426万支,实际接种的是1097万支,这意味着还有300多万支的流感疫苗并未被接种,但也不排除有个别接种点有流感疫苗短缺现象。2018年底,全国多家媒体报道出现流感疫苗短缺现象。对此,国家卫健委疾控局副局长雷正龙解释,由于疫苗生产企业从世界卫生

《儿童流感的预防与控制建议(2018-2019年)》解读

WHO 数据显示,全球每年有20%~30% 的儿童罹患季节性流感,其中5~9 岁儿童感染率最高。我国流感中心发布的检测报告显示,我国大多数省份已经进入2018—2019 年冬春季流感的流行季节,且儿童感染情况较严重,而接种流感疫苗是其他方法不可替代的最有效预防流感及其并发症的手段。为此,本期就美国儿科学会(AAP)感染性疾病委员会发布的《儿童流感的预防与控制建议(2018—2019 年)》主要更新

Baidu
map
Baidu
map
Baidu
map